The journal of nutrition, health & aging

, Volume 22, Issue 1, pp 165–173 | Cite as

Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation

  • E. Chaussade
  • Olivier Hanon
  • C. Boully
  • F. Labourée
  • L. Caillard
  • G. Gerotziafas
  • J.-S. Vidal
  • I. Elalamy



Few geriatric patients were included in studies on direct oral anticoagulants and data on dabigatran concentration and safety are needed in this population. Our objectives were to evaluate peak and trough dabigatran plasma concentrations over time in a geriatric population and to identify factors associated with dabigatran plasma concentrations and to assess the relationship with bleeding events.


Peak and trough dabigatran plasma concentration were performed 4,8,15,30,45 days after inception of dabigatran treatment in 68 consecutive patients≥75 years old hospitalized in a geriatric hospital with atrial fibrillation. Bleeding events were monitored for 1 year.


Mean age was 85.8(5.1) years old and 76.5% were women. Overall, 541 dabigatran plasma measurements (270 peak, 271 trough) were performed. Mean dabigatran concentrations of the 5 sequential measurements ranged 106-146ng/mL for peak and 66-84ng/mL for trough. Renal failure was associated with high peak and trough dabigatran concentration. Inter- and intra-individual coefficients of variation were 59.5% and 44.7% for peak and 74.5% and 44.6% for trough. Participants in the lower two tertiles of dabigatran concentration at day 8 (D8) remained below the 90th percentile (243.9ng/ml) on the next measurements. Bleeding events were associated with high trough dabigatran concentrations. Trough dabigatran concentration at D8>243.9ng/mL significantly predicted bleeding.


In this geriatric population, renal function and low albumin were associated with dabigatran concentrations. Despite large variability, participants in the lower two tertiles of dabigatran concentration at D8 remained below the 90th percentile on the following measurements. D8 dabigatran trough concentration≥243.9ng/mL identified patients at risk of bleeding.

Key words

Anticoagulants antithrombins atrial fibrillation aged 80 and over 


  1. 1.
    Heeringa J, van der Kuip DAM, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006. Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001. Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.CrossRefPubMedGoogle Scholar
  3. 3.
    Hanon O, Assayag P, Belmin J et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis. 2013;106:303–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRefPubMedGoogle Scholar
  5. 5.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Peterson GM, Boom K, Jackson SL, Vial JH. Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J. 2002;32:15–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Hanon O, Vidal JS, Pisica-Donose G et al. Therapeutic management in ambulatory elderly patients with atrial fibrillation: the S.AGES cohort. J Nutr Health Aging. 2015;19:219–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.e4.CrossRefPubMedGoogle Scholar
  9. 9.
    Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation. 2015;132:194–204.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sardar P, Chatterjee S, Lavie CJ et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50. randomized trials. Int J Cardiol. 2015;179:279–87.CrossRefPubMedGoogle Scholar
  12. 12.
    Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2. doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Turnheim K. Drug therapy in the elderly. Exp Gerontol. 2004;39:1731–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45:243–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Burton DGA, Allen MC, Bird JLE, Faragher RGA. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J Pharm Pharmacol. 2005;57:671–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Noble RE. Drug therapy in the elderly. Metabolism. 2003;52:27–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2013;126:289–96.CrossRefPubMedGoogle Scholar
  18. 18.
    Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients is caution necessary?: Comment on «The use of dabigatran in elderly patients». Arch Intern Med. 2011;171:1287–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.CrossRefPubMedGoogle Scholar
  21. 21.
    Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMedGoogle Scholar
  23. 23.
    Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–37.CrossRefPubMedGoogle Scholar
  24. 24.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMedGoogle Scholar
  25. 25.
    Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMedGoogle Scholar
  28. 28.
    Antovic JP, Skeppholm M, Eintrei J et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013;69:1875–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMedGoogle Scholar
  31. 31.
    European Medicines Agency. Pradaxa Summary of Product Characteristics. European Medicines Agency. 2013.Google Scholar
  32. 32.
    Testa S, Tripodi A, Legnani C et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016;137:178–83.CrossRefPubMedGoogle Scholar
  33. 33.
    Chan NC, Coppens M, Hirsh J et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015;13:353–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Levey AS, Eckardt K, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMedGoogle Scholar
  35. 35.
    FDA. Summary Review for Pradaxa. 2010.Google Scholar
  36. 36.
    Douxfils J, Mullier F, Dogne J. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14:1283–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Hawes EM, Deal AM, Funk-Adcock D et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493–502.CrossRefPubMedGoogle Scholar
  39. 39.
    Curvers J, van de Kerkhof D, Stroobants AK, van den Dool E, Scharnhorst V. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? Am J Clin Pathol. 2012;138:551–8.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer-Verlag France SAS, part of Springer Nature 2018

Authors and Affiliations

  • E. Chaussade
    • 1
    • 2
  • Olivier Hanon
    • 1
    • 2
    • 5
  • C. Boully
    • 1
    • 2
  • F. Labourée
    • 1
    • 2
  • L. Caillard
    • 1
    • 2
  • G. Gerotziafas
    • 3
    • 4
  • J.-S. Vidal
    • 1
    • 2
  • I. Elalamy
    • 3
    • 4
  1. 1.APHP, Hôpital BrocaParisFrance
  2. 2.Université Paris Descartes, Sorbonne Paris CitéParisFrance
  3. 3.APHP, HUEP, Hôpital TENON, Service d’Hématologie BiologiqueParisFrance
  4. 4.UMR S 938 UPMC Paris 6ParisFrance
  5. 5.Hôpital BrocaParisFrance

Personalised recommendations